Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sernova ( (TSE:SVA) ) just unveiled an update.
Sernova Biotherapeutics has appointed Dr. Pericles Calias as Chief Development Officer and Head of R&D to enhance its operational depth and expertise in cell therapy. Dr. Calias brings extensive experience in drug product development and regulatory approvals, which is expected to accelerate the advancement of Sernova’s Cell Pouch Bio-hybrid Organ as a functional cure for T1D, potentially transforming treatment paradigms and benefiting patients with chronic diseases.
More about Sernova
Sernova Biotherapeutics is a clinical-stage regenerative medicine company focused on developing bio-hybrid organs to treat chronic diseases. Their primary product is the Cell Pouch, which is combined with human donor cells or stem-cell derived islet-like clusters to create functional cures for type 1 diabetes (T1D) and thyroid disorders.
YTD Price Performance: -19.57%
Average Trading Volume: 134,568
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$60.77M
See more data about SVA stock on TipRanks’ Stock Analysis page.